Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer.
Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer.
复制标题
DOI：
10.3892/or.17.6.1333
复制
发表时间：
2007-06
期刊：
影响因子：
4.2
通讯作者：
Miho Takao;A. Okamoto;T. Nikaido;M. Urashima;S. Takakura;M. Saito;M. Saito;S. Okamoto;O. Takikawa;H. Sasaki;M. Yasuda;K. Ochiai;Tadao Tanaka
中科院分区：
文献类型：
--
作者：
Miho Takao;A. Okamoto;T. Nikaido;M. Urashima;S. Takakura;M. Saito;M. Saito;S. Okamoto;O. Takikawa;H. Sasaki;M. Yasuda;K. Ochiai;Tadao Tanaka
我们以前报道过吲哚胺-2，3-双加氧酶（IDO）与紫杉醇耐药相关，并且IDO可作为卵巢浆液性腺癌（SA）预后不良的标志物。在这项研究中，探索IDO在各种组织学类型的卵巢癌的发展中的作用，我们进一步研究了IDO的表达不仅在SA，而且在其他类型的卵巢癌。在知情同意的情况下，通过免疫组织化学分析了总共122例卵巢癌（包括40例SA、67例透明细胞腺癌（CCA）和15例卵巢样腺癌（EA））的IDO蛋白表达。其中CCA合并子宫内膜异位症11例，淋巴结转移60例。我们根据IDO染色模式将样本分为四类。IDO染色在SA、CCA和EA中的阳性率分别为57.5%、49.2%和73.3%。Kaplan-Meier生存曲线显示，对于接受最佳手术和紫杉醇-卡铂（TC）化疗作为一线方案的晚期（III期和IV期）SA患者（n=33），染色评分与总生存期之间存在明确关系。在CCA病例中，IDO染色评分与总生存率无关。11例CCA合并子宫内膜异位症中8例（72.7%）IDO染色与CCA和子宫内膜异位症完全一致。在60例有淋巴结转移的病例中，有43例（71.6%）的IDO表达与原发灶和转移灶相一致。这些结果表明，IDO蛋白的合成增加与只有在浆液性卵巢癌中的生存受损呈正相关。
We previously reported that indoleamine-2,3-dioxygenase (IDO) is associated with paclitaxel resistance and that IDO serves as a marker of poor prognosis in ovarian serous adenocarcinomas (SA). In this study, to explore the role of IDO in the development of various histological types of ovarian cancer, we further examined IDO expression not only in SA but also in other types of ovarian cancers. Expression of IDO protein was analyzed by immunohistochemistry for a total of 122 ovarian cancers including 40 SA, 67 clear cell adenocarcinomas (CCA), and 15 endometrioid adenocarcinomas (EA) with informed consent. Among these cases, there were 11 CCA accompanied with endometriosis and 60 cases with lymph node metastasis. We classified the samples into four categories by IDO staining pattern. IDO staining was positive in 57.5% of SA, 49.2% of CCA, and 73.3% of EA, respectively. The Kaplan-Meier survival curve showed a clear relationship between staining score and overall survival for patients with advanced (stages III and IV) SA (n=33) who underwent optimal surgery and paclitaxel-carboplatin (TC) chemotherapy as a first-line regimen. There was no association between IDO staining score and overall survival in the CCA cases. Eight of 11 cases (72.7%) of CCA accompanied by endometriosis presented identical staining patterns of IDO between CCA and endometriosis. In 43 of 60 cases (71.6%) with lymph node metastasis, the staining patterns of IDO showed a correspondence between the primary lesion and metastatic site. These results suggested that the increased synthesis of IDO protein was positively associated with impaired survival only in the serous type of ovarian cancer.